which can shorten treatment duration and cost, include hypofractionated WBI (HFRT), accelerated partial breast irradiation (APBI) and endocrine therapy-alone (ET-alone). We sought to evaluate the proportion of patients that would be eligible for these alternatives using the National Cancer Database (NCDB). Methods: Using the 2016 dataset, 1,895,245 patients with Stage I-III breast cancer were identified. Men, patients age <40 years, unknown pathologic stage, and unknown estrogen receptor status were excluded. A total of 1,157,788 patients were eligible for this analysis, of which 819,210 patients were pN0. Eligibility for HFRT, APBI and ET-alone was defined using eligibility criteria from large clinical trials as well as consensus guidelines. Results: Of the patients with pN0 breast cancer, 20.6% and 37.0% were eligible for endocrine therapy (ET)-alone based on the CALGB 9343 and PRIME-II trials, respectively. In terms of HFRT, 72.5% and 50.4%were eligible based on the IMPORT LOW trial and ASTRO HFRT guidelines, respectively. Based on the IMPORT LOW trial, the GEC-ESTRO trial, ASTRO APBI guidelines, ABS APBI guidelines, and GEC-ESTRO APBI guidelines, 72.5%, 86.1%, 39.0%, 72.5%, 45.7%, respectively, were eligible for APBI. Of the women eligible for HFRT per ASTRO guidelines (nZ413,074), approximately 90% were eligible for APBI and 50% were eligible for ET-alone. Of the women eligible for APBI, approximately 50% were eligible for ET-alone and 100% were eligible for HFRT.
Purpose: To assess the impact of axillary ultrasound (AUS) on treatment of breast cancer. The pre-operative (AUS) with or without ultrasound guided biopsy is being increasingly used in the pre-operative workup of breast cancer. We sought to assess the impact of AUS on treatment of breast cancer. Methods: Retrospective chart review of 162 consecutive patients newly diagnosed with breast cancer between 2010 and 2016. All women underwent axillary ultrasonography followed by percutaneous core biopsy of lymph nodes if the AUS results were suspicious for cancer involvement. Results: All except 8 patients were T1-T2. 8 patients were Tis clinical stage group, 75 were IA, 1 was IB, 44 were IIA, 20 were IIB, 11 were IIIA, 2 were IIIB, and 1 was IIIC. 65 (40%) of women underwent core biopsies of axillary lymph nodes before surgery. 42 (65%) of these, had a positive biopsy. Compared to patients with negative AUS and/or negative axillary biopsy, AUS lymph node biopsy positive was significantly associated with: receipt of mastectomy versus lumpectomy (p-value < 0.0035); receipt of neoadjuvant chemotherapy versus adjuvant or no chemotherapy (p-value < 0.0001); planned axillary lymph node dissection versus sentinel lymph node biopsy (p-value < 0.0001); receipt of breast MRI (p-value < 0.0001); lymph node radiation versus no lymph node radiation (p-value < 0.0001); and family history of breast cancer (p-value < 0.0342). Conclusions: Our findings show that patients with a diagnosis of breast cancer and positive axillary lymph node biopsy with AUS were more likely to receive mastectomy, planned axillary lymph node dissection, neoadjuvant chemotherapy, breast MRI, adjuvant radiation and adjuvant axillary lymph nodal radiation. Previous studies of this subtype demonstrated a higher propensity for lymph node metastases compared with invasive ductal carcinoma. Due to this lymphotropic nature, patients with IMPC were once thought to experience worse survival outcomes compared to invasive ductal carcinoma. Our group previously performed analyses of IMPC patients using the Surveillance, Epidemiology, and End Results database and found survival outcomes comparable to invasive ductal carcinoma. In this study, we aim to validate those findings using the National Cancer Data Base (NCDB). Materials/Methods: The NCDB was used to retrieve patients with biopsyproven IMPC diagnosed from 2004-2012. Cox multivariate regression was used to determine prognostic factors. Results: Of 1,096,468 patients with invasive breast cancer, 1,818 (0.2%) had IMPC and sufficient follow-up. At a median follow-up of 4 years, 5yr overall survival (OS) was 87.5% (95% Confidence Interval 85.6-89.4%). At presentation, 55.2% of patients had nodal involvement. Patients with 4+ positive lymph nodes had worse OS (hazard ratio [HR], 3.78; P<0.001) than patients with node-negative disease. However, those with 1-3 positive nodes had an OS similar to patients with node-negative disease. Other poor prognostic factors included comorbidity score >1 (HR 5.56; P<0.001) and distant metastasis (HR 5.37; P<0.001). Factors associated with a good prognosis included age <50 (HR 0.54; PZ0.002), receipt of external beam radiotherapy (HR 0.53; P<0.001), Hispanic/Asian ethnicity (HR 0.48; PZ0.011), and ER-positivity (HR 0.48; P<0.001). Conclusions: Although IMPC has a high propensity for lymph node metastasis, OS is comparable to the historical OS of invasive ductal carcinoma. The receipt of radiotherapy was associated with a better prognosis on multivariate analysis. This is the largest study of IMPC to date, and these findings validate our previous population-based analysis in a more contemporary patient population.
(P009) Assessment of Lumpectomy Cavity Radiotherapy Boost Volume With Repeat CT Simulation Aman Saini, BBA, 1 Steven Sckolnik, MD, 2 and Anushka Patel, MD 2 ; 1 Midwestern University, 2 Arizona Center for Cancer Care Purpose: Lumpectomy cavity (LC) radiotherapy boost after breast conserving surgery and whole breast irradiation (WBRT) reduces local cancer recurrence. Radiotherapy boost correlates with increased rates of fibrosis and may have worse cosmetic outcomes. LC volumes and subsequent boost volumes may decrease with increasing time from surgery. This study evaluates the timing of CT simulation and radiotherapy technique for cavity directed radiotherapy boost. We seek to determine if repeat CT simulation results in smaller boost volumes which may minimize treatment related toxicity and maximize local tumor control. Patients & Methods: A retrospective chart review examined 47 consecutive patients receiving WBRT with LC boost after breast conserving surgery. All patients underwent CT simulation prior to WBRT and repeat CT simulation prior to LC boost. The WBRT prescription dose ranged from 4240-5040cGy and boost from 1000-1600cGy. The LC was contoured on the pre and post CT images and delineated by surgical clips and seroma cavity. Results: 40 of 47 patients reviewed were found to have decreased LC volumes. The mean initial and repeat LC volumes were 71.1cc and 42.6cc respectively. Initial volumes greater than 60cc had a greater percentage decrease in LC volume at time of repeat simulation, 42% vs 30% (pZ0.01). Patients who underwent initial LC evaluation less than 4 weeks after surgery had a greater percent decrease in mean repeat cavity volumes compared to those greater than 4 weeks out from surgery, 53% vs 24%. Conclusions: Patients undergoing WBRT with LC radiotherapy boost were found to have decreased cavity volume with repeat CT simulation. Factors that correlate to reduced volume are larger initial cavity volume and shorter time interval from surgery. These factors help to identify patients who will benefit from repeat CT simulation prior to boost planning and will subsequently have smaller volumes of radiation to normal breast tissue. Background: For locally advanced breast cancer (LABC), an incomplete clinical and pathological response to neoadjuvant chemotherapy is an adverse prognostic factor. The safety and utility of adding concurrent chemotherapy to adjuvant radiation therapy in high-risk patients has not yet been determined. Purpose: Report our experience using concurrent chemotherapy with adjuvant radiotherapy for high-risk breast cancer patients who have an incomplete pathological response to neoadjuvant chemotherapy. Methods: We conducted a retrospective study of breast cancer patients treated definitively with trimodality therapy between January 1, 2007, and January 1, 2014. The decision to use concurrent chemotherapy with adjuvant radiation was based on response to neoadjuvant treatment. Results: Sixty-four patients met inclusion criteria, 39 receiving adjuvant radiotherapy alone and 25 received adjuvant chemoradiation. Pathologic T and N stages were different between groups, with a higher proportion of residual disease in those who later received adjuvant chemoradiation. Concurrent chemoradiation was associated with increased Grade 3 radiodermatitis (20% vs. 3%, P Z .05) but was otherwise well tolerated. Locoregional recurrences (LRR) occurred in 7 patientsdall of whom had received concurrent chemotherapy. No statistically significant differences in late toxicity were detected between groups. Conclusions: Concurrent chemoradiation for high-risk breast cancer was well tolerated in these high-risk patients. Efficacy cannot yet be determined from this observational study. Prospective evaluation of the efficacy of concurrent chemoradiation with capecitabine is warranted. Background: The role for postmastectomy radiation therapy (PMRT) for women pT3N0M0 breast cancer is controversial. We sought to determine the benefit of PMRT in this cohort using the National Cancer Database (NCDB). Methods: We used the NCDB to analyze women with pT3N0M0 breast cancer who received mastectomy with or without adjuvant radiation between 2004-2012. We excluded from analysis men, women 18 years, neoadjuvant or unknown radiation or chemotherapy status, unknown estrogen or progesterone receptor status, unknown surgical margin status, histology other than invasive ductal or lobular carcinoma, and if death occurred < 3 months after diagnosis. A total of 4291 patients were included for analysis. Chi-squared analysis was used to compare patient characteristics. Univariate (UVA) and multivariate (MVA) Cox proportional hazards modeling was used to identify factors associated with survival. Propensity score matching was performed to address potential confounding variables. Survival analysis was performed using Kaplan-Meier and shared frailty models. Results: Of the 4291 women analyzed, 2030 (47%) received PMRT. On MVA, PMRT (HR 0.72, p<0.001), chemotherapy (HR 0.44, p<0.001), and hormone therapy (HR 0.42, p<0.001) were associated with improved survival. After propensity score matching, a matched cohort of 2800 women was analyzed. At 5 years, overall survival was 83.7% and 79.8% with and without PMRT, respectively (p<0.001). This difference in survival benefit increased with time. At 10 years, overall survival was 67.4% and 59.2% with and without PMRT, respectively. Between 2004-2012, PMRT was utilized in 45%-50% of cases with no significant change in utilization over time, while utilization of chemotherapy decreased (65% to 52%) and receipt of hormone therapy increased (50% to 69%). Conclusions: PMRT was associated with improved overall survival in women with pT3N0M0 breast cancer, even after accounting for age and receipt of systemic therapies. PMRT should be strongly considered in women with pT3N0M0 breast cancer. Introduction: National guidelines include collagen vascular disease (CVD) as a relative contraindication to breast conserving therapy (BCT) out of concern for greater radiation toxicity. We studied the use of radiation in patients with breast cancer and CVD and the incidence of acute and late toxicity. We hypothesized that patients with CVD may be undertreated with postlumpectomy radiation compared to our institutional rate of approximately 95%. Methods: With IRB approval, we retrospectively searched for women with diagnosis codes for breast cancer and lupus variants. Acute toxicity was defined as during or within 1 month of radiation versus late toxicity >1 month. Results: We identified 71 cancers among 64 patients with a diagnosis of systemic lupus erythematosus or a variant (discoid or cutaneous), and breast cancer, between June 1997 and July 2015. 21 (31%) had an additional CVD, including undifferentiated connective tissue disease, fibromyalgia, rheumatoid arthritis, Sjogren disease, dermatomyositis, and CREST syndrome (limited scleroderma). No patients had systemic sclerosis (scleroderma). 53 patients carried a breast cancer stage for which radiation could be considered, including 38 eligible for BCT. 22 (58%) underwent lumpectomy, and of those, 14 (64%) subsequently received radiation.
A total of 31 women received radiation as part of BCT or another indication. Acute and late toxicity data were available for 20 and 30 women. Six (30%) had grade 2 acute dermatitis, 1 (5%) grade 3, and 0 grade 4 or higher. No patients had grade 3 or higher late toxicities; 2 (7%) had grade 2 late effects. 1 had skin/soft tissue change and edema, and 1 had arm pain and lymphedema. Conclusions: Despite low rates of toxicity, women with breast cancer and CVD were substantially less likely to receive postlumpectomy radiation than institutional controls. Radiation can be more strongly recommended for this patient population.
